Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating Expenses:        
Research and development $ 1,307,000 $ 1,364,000 $ 3,868,000 $ 5,109,000
Selling, general and administrative (including $0 and $547,000 from stock compensation granted to officers, directors, and employees and for services for the three months ended September 30, 2024 and 2023, respectively, and $222,000 and $1,767,000 for the nine months ended September 30, 2024 and 2023, respectively) 2,297,000 1,758,000 6,733,000 5,299,000
Loss from Operations (3,604,000) (3,122,000) (10,601,000) (10,408,000)
Other Income (Expense)        
Interest income 96,000 216,000 343,000 600,000
Interest expense (213,000)
Change in fair value of warrant liability 95,000 485,000 870,000 4,796,000
Gain on extinguishment of debt 547,000
Unrealized gain on marketable securities 2,000 5,000 1,000 43,000
Total Other Income, Net 193,000 706,000 1,214,000 5,773,000
Net Loss $ (3,411,000) $ (2,416,000) $ (9,387,000) $ (4,635,000)
Net Loss Per Share - Basic $ (1.53) $ (1.77) $ (5.28) $ (3.47)
Net Loss Per Share - Diluted $ (1.53) $ (1.77) $ (5.28) $ (3.47)
Weighted average common shares outstanding - basic 2,234,328 1,367,206 1,777,313 1,336,532
Weighted average common shares outstanding - diluted 2,234,328 1,367,206 1,777,313 1,336,532